Trikafta

DRUG4 trials

Sponsors

Emory University, University of British Columbia

Conditions

Cystic FibrosisLung DiseasesNon-cystic Fibrosis Bronchiectasis

Phase 2

Trikafta in Cystic Fibrosis Patients

CompletedNCT03506061

Emory UniversityCystic Fibrosis

Start: 2019-09-04End: 2024-02-13Updated: 2026-08-11

Phase 4

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

CompletedNCT05743946

Emory UniversityNon-cystic Fibrosis Bronchiectasis

Start: 2023-04-18End: 2025-12-23Updated: 2026-02-09

Unknown Phase

Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF

RecruitingNCT05200429

University of British ColumbiaCystic Fibrosis

Start: 2021-11-01End: 2027-12-31Target: 500Updated: 2022-01-20

Trikafta Exercise Study in Cystic Fibrosis

RecruitingNCT05279040

University of British ColumbiaCystic Fibrosis, Lung Diseases

Start: 2021-11-10End: 2027-01-01Target: 20Updated: 2026-05-18

Related Papers

Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol

PLoS ONE2025-02-143 citations

Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTR<sup>N1303K</sup> in the USA: a prospective, multicentre, open-label, single-arm trial.

2024-08-2610 citations